Company news
Ataibeckley Inc. (NASDAQ:ATAI) news
Every Ataibeckley Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases — page 2
atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health
January 9, 2025
atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
November 12, 2024
atai Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit
October 14, 2024
atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
September 3, 2024
atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
August 12, 2024
atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Buccal Film DMT)
August 12, 2024
atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference
August 6, 2024
atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference
June 25, 2024
atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a
June 19, 2024
atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference
May 30, 2024
atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors
May 22, 2024
atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates
May 14, 2024
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
April 23, 2024
atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
April 16, 2024
atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights
March 27, 2024
atai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression
March 26, 2024
atai Life Sciences advances VLS-01 for treatment-resistant depression
March 11, 2024
atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01
March 3, 2024
atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference
February 27, 2024
atai Life Sciences Appoints Anne Johnson as Chief Financial Officer
February 5, 2024
atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics
January 3, 2024
atai Life Sciences Announces Positive Topline Results from Single Ascending Dose Phase 1 Study with EMP-01 (R-MDMA)
January 1, 2024
atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights
November 13, 2023
Cognito Therapeutics Appoints Greg Weaver as Chief Financial Officer
October 16, 2023
atai Life Sciences to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit
October 5, 2023
atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants
October 1, 2023
atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
September 13, 2023
atai Life Sciences to Participate in Upcoming September Investor Conferences
September 5, 2023
atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)
August 9, 2023
atai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)
August 7, 2023
atai Life Sciences to Participate in Upcoming June Investor Conferences
May 31, 2023
atai Life Sciences Reports First Quarter 2023 Financial Results and Announces Pipeline Highlights and Updates
May 10, 2023
atai Life Sciences to Participate in Upcoming May Investor Conference
May 1, 2023
atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late Breaking Poster Presentation at the 2023 SOBP Annual Meeting
April 27, 2023
atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)
April 12, 2023
atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights
March 23, 2023
atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates
March 5, 2023
atai Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference
February 28, 2023
atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917
January 8, 2023
atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression
January 5, 2023
atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101
December 22, 2022
atai Life Sciences Initiates Phase 2b proof-of-concept trial of RL-007 for Cognitive Impairment Associated with Schizophrenia
December 18, 2022
The atai Fellowship Fund in Psychedelic Neuroscience Announces its First Cohort at Massachusetts General Hospital
December 15, 2022
atai Life Sciences Strengthens Leadership Team with Appointment of Dr. Sahil V. Kirpekar as Chief Business Officer
November 28, 2022
atai Life Sciences and Massachusetts General Hospital Announce Initiation of Clinical Study Investigating Neuroplasticity Biomarkers in Treatment-Resistant Depression Patients Undergoing Ketamine Treatment
November 16, 2022
atai Life Sciences Reports Third Quarter 2022 Financial Results and Business Update
November 9, 2022
atai Life Sciences to Participate in November Investor Events & Healthcare Conferences
October 31, 2022
atai Life Sciences to Announce Third Quarter 2022 Financial Results and Business Update
October 31, 2022
atai Life Sciences Company, Perception Neuroscience, Completes Enrollment for Phase 2a Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression
October 24, 2022
atai Life Sciences Announces R&D Day Agenda
October 19, 2022